CORDIS · 101129778 · HORIZON
INVECTA Integrative characterisation of Novel adenovirus VECtors aimed at Therapeutic Applications
Coordinator: RUDER BOSKOVIC INSTITUTE (HR)
Adenovirus based vectors have potential translational and commercial values and are studied as vectors for gene transfer and vaccination . Low seroprevalence adenoviruses are efficacious platforms for vector design, warranting their thorough investigation. Therefore, the main objective of INVECTA is to establish a collaborative effort for the study of scientific problems related to development of novel low seroprevalence adenovirus based vectors aimed at their therapeutic usage, with an emphasis on training both experienced and early stage researchers in adenovirus research, as well as establ…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
0 EU contribution: €198k awarded to the consortium. The project runs over approximately 4 years from 2023-12-01 to 2027-11-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from HR
see all →- MARBLE — Centre of Excellence in Maritime Robotics and Technologies for Sustainable Blue Economy101136349 · HORIZON · €15.0M
- ANEUPLOIDY — Molecular origins of aneuploidies in healthy and diseased human tissues855158 · H2020 · €10.0M
- InnoThyroGen — Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence101187880 · HORIZON · €4.9M
- INNOMOL — Enhancement of the Innovation Potential in SEE through new Molecular Solutions in Research and Development316289 · FP7 · €4.7M
- GLOWBRAIN — Combining Stem Cells and Biomaterials for Brain Repair - Unlocking the Potential of the Existing Brain Research through Innovative In Vivo Molecular Imaging316120 · FP7 · €3.8M
- ACROSS — Centre of Research Excellence for Advanced Cooperative Systems285939 · FP7 · €3.4M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-TMA-MSCA-SE funding scheme.
- What is the EU contribution?
- The European Commission contributes €198k.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-MSCA-2022-SE-01.
- Who coordinates the project?
- The project is coordinated by RUDER BOSKOVIC INSTITUTE (HR).
- What is the project timeline?
- The project runs from 2023-12-01 to 2027-11-30 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101129778.